The application of NMR in tumor angiogenesis research

Dadiani, Maya; Furman‐Haran, Edna; Degani, Hadassa

doi:10.1016/j.pnmrs.2006.06.001

Cited by 14 publications

(9 citation statements)

References 163 publications

(202 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These properties make gadolinium chelates the preferred contrast agents for MRI. The first CA approved for clinical MRI applications in humans was the anionic gadolinium diethylenetriaminepentaacetate complex, Gd-DTPA, which is now routinely used for contrast MRI in clinical practice [10], [28].…”

Section: ) Contrast Agent Properties and Signal Calibration: A) Dynamentioning

confidence: 99%

“…To acquire the T1-weighted images, spoiled gradient echo sequences (FLASH) are typically used [10], [112], [115], [116]. The resulting signal intensity is described as…”

Section: ) Contrast Agent Properties and Signal Calibration: A) Dynamentioning

confidence: 99%

“…Neoangiogenic vessels differ from normal capillaries, showing a high degree of tortuosity and irregularity. They also exhibit a higher permeability, arteriovenous shunting, chaotic flow patterns, and fragility [2], [3], [7], [10], [11]. These abnormalities in the vascular architecture make the hemodynamic changes in the blood flow more complex to analyze.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Mathematical Models of Contrast Transport Kinetics for Cancer Diagnostic Imaging: A Review

Turco

Wijkstra

Mischi

2016

IEEE Rev. Biomed. Eng.

View full text Add to dashboard Cite

Angiogenesis plays a fundamental role in cancer growth and the formation of metastasis. Novel cancer therapies aimed at inhibiting angiogenic processes and/or disrupting angiogenic tumor vasculature are currently being developed and clinically tested. The need for earlier and improved cancer diagnosis, and for early evaluation and monitoring of therapeutic response to angiogenic treatment, have led to the development of several imaging methods for in vivo noninvasive assessment of angiogenesis. The combination of dynamic contrast-enhanced imaging with mathematical modeling of the contrast agent kinetics enables quantitative assessment of the structural and functional changes in the microvasculature that are associated with tumor angiogenesis. In this paper, we review quantitative imaging of angiogenesis with dynamic contrast-enhanced magnetic resonance imaging, computed tomography, and ultrasound.

show abstract

Section: ) Contrast Agent Properties and Signal Calibration: A) Dynamentioning

confidence: 99%

“…To acquire the T1-weighted images, spoiled gradient echo sequences (FLASH) are typically used [10], [112], [115], [116]. The resulting signal intensity is described as…”

Section: ) Contrast Agent Properties and Signal Calibration: A) Dynamentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Mathematical Models of Contrast Transport Kinetics for Cancer Diagnostic Imaging: A Review

Turco

Wijkstra

Mischi

2016

IEEE Rev. Biomed. Eng.

View full text Add to dashboard Cite

show abstract

“…The inclusion of a water exchange term in this model, termed the shutter-speed model, by adding the lifetime of water in the intracellular compartment as an additional free parameter, improved the quality of the fit in animal model tumors. However, the physiological relevance of the resultant lifetime of water in the intracellular compartment is unclear, as the large values and extensive variations in the lifetimes appear to be inconsistent with water lifetime in cancer cells (59). In human studies with the shutter-speed model, Li et al (24) analyzed six breast lesions (three infiltrating ductal carcinoma and three fibroadenoma) and compared the parameters with those obtained using the standard Tofts model.…”

Section: Conversion From Signal Intensity or Signal Enhancement Of T mentioning

confidence: 99%

Model‐based and model‐free parametric analysis of breast dynamic‐contrast‐enhanced MRI

Eyal

Degani

2007

NMR in Biomedicine

Self Cite

View full text Add to dashboard Cite

A wide range of dynamic-contrast-enhanced (DCE) sequences and protocols, image processing methods, and interpretation criteria have been developed and evaluated over the last 20 years. In particular, attempts have been made to better understand the origin of the contrast observed in breast lesions using physiological models that take into account the vascular and tissue-specific features that influence tracer perfusion. In addition, model-free algorithms to decompose enhancement patterns in order to segment and classify different breast tissue types have been developed. This review includes a description of the mechanism of contrast enhancement by gadolinium-based contrast agents, followed by the current status of the physiological models used to analyze breast DCE-MRI and related critical issues. We further describe more recent unsupervised and supervised methods that use a range of different common algorithms. The model-based and model-free methods strive to achieve scientific accuracy and high clinical performance--both important goals yet to be reached.

show abstract

“…These advantages have already been exploited by many groups who have evaluated MRI alone, or in combination with MRS, to stage and characterize prostate cancer. The development and application of dynamic contrast enhanced MRI has provided a potential tool to image the manifestations of angiogenesis in tumors, in general [10, 11, 13, 14], and in prostate cancer, specifically [10, 11]. The close connection between DCEMRI and angiogenesis and the current consensus that more aggressive tumors exhibit greater angiogenesis form the basis for suggesting that DCEMRI is an “imaging” biomarker.…”

mentioning

confidence: 99%

An illustration of the potential for mapping MRI/MRS parameters with genetic over-expression profiles in human prostate cancer

Lenkinski

Bloch

Liu

et al. 2008

Magn Reson Mater Phy

View full text Add to dashboard Cite

Magnetic resonance imaging (MRI) and MR spectroscopy can probe a variety of physiological (e.g. blood vessel permeability) and metabolic characteristics of prostate cancer. However, little is known about the changes in gene expression that underlie the spectral and imaging features observed in prostate cancer. Tumor induced changes in vascular permeability and angiogenesis are thought to contribute to patterns of dynamic contrast enhanced (DCE) MRI images of prostate cancer even though the genetic basis of tumor vasculogenesis is complex and the specific mechanisms underlying these DCEMRI features have not yet been determined. In order to identify the changes in gene expression that correspond to MRS and DCEMRI patterns in human prostate cancers, we have utilized tissue print micropeel techniques to generate "whole mount" molecular maps of radical prostatectomy specimens that correspond to pre-surgical MRI/MRS studies. These molecular maps include RNA expression profiles from both Affymetrix GeneChip microarrays and quantitative reverse transcriptase PCR (qrt-PCR) analysis, as well as immunohistochemical studies. Using these methods on patients with prostate cancer, we found robust over-expression of choline kinase a in the majority of primary tumors. We also observed overexpression of neuropeptide Y (NPY), a newly identified angiogenic factor, in a subset of DCEMRI positive prostate cancers. These studies set the stage for establishing MRI/MRS parameters as validated biomarkers for human prostate cancer. Keywords MRI; prostate; gene expressionThe wide range of biologic activity exhibited by prostate cancer creates dilemmas for the management of individuals with known or suspected disease. Prostate cancer is one of the few cancers that can grow so slowly that it never threatens the lives of many patients. Yet, in some patients, the disease spreads beyond the gland, and is incurable. This characteristic of prostate cancer is reflected in the fact that, although one out of six men will develop prostate cancer, only one out of thirty five will die of the disease [1].Corresponding Author: Robert E. Lenkinski, Department of Radiology, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston MA, USA 02215, Tel: 617-667-0274, Fax: 617-667-7917, Email: rlenkins@bidmc.harvard Prostate cancer patients are being identified at an earlier and potentially treatable stage because of the adoption of screening using serum prostate-specific antigen (PSA) and transrectal ultrasound (TRUS) guided biopsy [2][3][4][5][6]. A major challenge to the medical community is to characterize the behavior of an individual patient's prostate cancer and to select the appropriate level of management while preserving the patient's quality of life. Current pre-treatment paradigms have significant limitations, both individually and collectively. One of the most widely used pretreatment paradigms is based on the Partin tables [7,8], which are derived from a combination of demographic factors, as well as the Gleason score from biopsy sa...

show abstract

The application of NMR in tumor angiogenesis research

Cited by 14 publications

References 163 publications

Mathematical Models of Contrast Transport Kinetics for Cancer Diagnostic Imaging: A Review

Mathematical Models of Contrast Transport Kinetics for Cancer Diagnostic Imaging: A Review

Model‐based and model‐free parametric analysis of breast dynamic‐contrast‐enhanced MRI

An illustration of the potential for mapping MRI/MRS parameters with genetic over-expression profiles in human prostate cancer

Contact Info

Product

Resources

About